Nicole Casasanta, MD
@ncasasanta.bsky.social
Heme/Onc Fellow @YaleCancer | Aspiring Breast Oncologist interested in clinical/translational research
🔹highest risk >6% 5 yr; high penetrant variant: mammo alt MRI q6 m
🔹elevated risk 2.5 risk percentile by age: annual mammo + RRcounseling
🔹average risk: biennial mammo
🔹low risk 40-49 yrs & <1.3%: no screening until >1.3% or 50 yrs
#bcsm
🔹elevated risk 2.5 risk percentile by age: annual mammo + RRcounseling
🔹average risk: biennial mammo
🔹low risk 40-49 yrs & <1.3%: no screening until >1.3% or 50 yrs
#bcsm
December 12, 2025 at 11:17 PM
🔹highest risk >6% 5 yr; high penetrant variant: mammo alt MRI q6 m
🔹elevated risk 2.5 risk percentile by age: annual mammo + RRcounseling
🔹average risk: biennial mammo
🔹low risk 40-49 yrs & <1.3%: no screening until >1.3% or 50 yrs
#bcsm
🔹elevated risk 2.5 risk percentile by age: annual mammo + RRcounseling
🔹average risk: biennial mammo
🔹low risk 40-49 yrs & <1.3%: no screening until >1.3% or 50 yrs
#bcsm
💭How do we approach 1L HER2+ MBC in the context of HER2CLIMB05, DB-09, & PATINA?
🔍 Tune into #TumorBoardTuesday 12/16 where we discuss!
🔍 Tune into #TumorBoardTuesday 12/16 where we discuss!
December 11, 2025 at 5:12 AM
💭How do we approach 1L HER2+ MBC in the context of HER2CLIMB05, DB-09, & PATINA?
🔍 Tune into #TumorBoardTuesday 12/16 where we discuss!
🔍 Tune into #TumorBoardTuesday 12/16 where we discuss!
📍HER2+ T-DXd+P is likely the new 1L SOC but many questions remain in HR+ pts, QOL, & potential maintenance strategies
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients
June 2, 2025 at 4:52 PM
📍HER2+ T-DXd+P is likely the new 1L SOC but many questions remain in HR+ pts, QOL, & potential maintenance strategies
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients
🔹60% dc T-DXd, 21% for AEs, 11% pt decision vs T 3.4% for AEs
🔹12% developed ILD, 2 grade 5 events🫁
🔹use of ET in HR+ group remains low
🔹for control arm low utilization of T-DXd in 2nd line 10%
🔹still awaiting results of T-DXd monotx arm
🔹12% developed ILD, 2 grade 5 events🫁
🔹use of ET in HR+ group remains low
🔹for control arm low utilization of T-DXd in 2nd line 10%
🔹still awaiting results of T-DXd monotx arm
June 2, 2025 at 1:16 PM
🔹60% dc T-DXd, 21% for AEs, 11% pt decision vs T 3.4% for AEs
🔹12% developed ILD, 2 grade 5 events🫁
🔹use of ET in HR+ group remains low
🔹for control arm low utilization of T-DXd in 2nd line 10%
🔹still awaiting results of T-DXd monotx arm
🔹12% developed ILD, 2 grade 5 events🫁
🔹use of ET in HR+ group remains low
🔹for control arm low utilization of T-DXd in 2nd line 10%
🔹still awaiting results of T-DXd monotx arm
🔸 ctDNA+ TNBC pts after NAT strong predictor of recurrence HR 9.5 CI 2.6-35 p=0.0006
🔸 ctDNA+ in TNBC pts after NAT has the potential to become a strong prognostic marker that could guide adjuvant therapy decision making
#ASCO2025
🔸 ctDNA+ in TNBC pts after NAT has the potential to become a strong prognostic marker that could guide adjuvant therapy decision making
#ASCO2025
June 2, 2025 at 12:03 PM
🔸 ctDNA+ TNBC pts after NAT strong predictor of recurrence HR 9.5 CI 2.6-35 p=0.0006
🔸 ctDNA+ in TNBC pts after NAT has the potential to become a strong prognostic marker that could guide adjuvant therapy decision making
#ASCO2025
🔸 ctDNA+ in TNBC pts after NAT has the potential to become a strong prognostic marker that could guide adjuvant therapy decision making
#ASCO2025
🔹Imbalance between lines of therapy makes interpretation challenging
June 1, 2025 at 8:37 PM
🔹Imbalance between lines of therapy makes interpretation challenging